ASCO 2025 | Topline results from the SURPASS-ET trial: ropeginterferon alfa-2b versus anagrelide in ET

So there was a Phase III study comparing a novel interferon called ropeginterferon alfa-2b in patients with refractory ET comparing it to anagrelide. So patients that would fail hydroxyurea as a frontline approach, needed therapies, were randomized to either ropeginterferon alfa-2b or anagrelide. Top line results basically showed superiority of ropeginterferon alfa-2b for second line ET patients in every single primary and secondary endpoint. 

So the primary endpoints was control of the disease as a combined hematologic control, so complete hematologic remission, and no enlargement or progression of the spleen as well as symptoms. That was achieved much higher in patients with ropeginterferon alfa-2b than anagrelide, actually the rates were doubled, about 70 percent about 30 percent in anagrelide patients. 

Then in subpopulations or sub endpoints where we looked at the control of all other significant parameters so white cell, platelet, symptoms, spleen, the ropeginterferon alfa-2b delivered superior data. Excitingly, also in control of the mutations so JAK2 mutations as well as CALR mutations were decreased more with ropeginterferon alfa-2b and actually they were not decreased with anagrelide because the drug would not do it. And then also a nice control seen of vascular adverse events as well as myelofibrosis progression. So the top line results so far very positive, very superior for comparing a second line option for patients with essential thrombocythemia, they will either be receiving ropeginterferon alfa-2b or anagrelide.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.